We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Axsome Gets FDA Nod for New Migraine Drug Symbravo, Stock Rises
Read MoreHide Full Article
Axsome Therapeutics, Inc. (AXSM - Free Report) announced that the FDA has approved Symbravo (meloxicam and rizatriptan) for the acute treatment of migraine with or without aura in adults.
Per the company, Symbravo, a novel, oral medicine, offers a multi-mechanistic approach to treating migraine. It targets multiple pathways underlying a migraine attack.
AXSM expects to launch Symbravo in the United States in about four months.
Shares of AXSM were up 3.5% on Jan. 30 following the news announcement.
The stock has rallied 20.8% in the past year against the industry’s decline of 10.2%.
Image Source: Zacks Investment Research
More on AXSM's Newest Migraine Drug
The FDA for Symbravo was based on data from a comprehensive clinical program that consisted of multiple phase III studies, the MOMENTUM study, INTERCEPT and the phase III MOVEMENT long-term open-label safety study.
Data from the phase III MOMENTUM and INTERCEPT studies showed that 77% and 85% of patients who were treated with Symbravo did not require rescue medication within 24 hours after the dose, respectively.
Data from both these studies showed that treatment with Symbravo led to a statistically significantly greater percentage of patients achieving pain freedom and freedom from their most bothersome symptom versus placebo, two hours after dosing.
The MOVEMENT study demonstrated the long-term safety of Symbravo in the given patient population.
Also, treatment with Symbravo demonstrated superior efficacy across a broad range of migraine severity (mild, moderate, and severe).
FDA Nod for Symbravo Diversifies AXSM's Product Portfolio
The latest FDA nod for Symbravo diversifies Axsome’s commercial drug portfolio. The company currently markets Auvelity (AXS-05) for treating major depressive disorder (MDD) and Sunosi (solriamfetol) for treating narcolepsy.
Auvelity was launched in the United States in 2022 for the treatment of MDD, making it the first approved drug in the company’s portfolio. The drug generated sales worth $198.8 in the first nine months of 2024, reflecting an increase of 145.4% year over year in the United States.
Axsome’s second marketed drug, Sunosi, is approved for treating narcolepsy. The company acquired U.S. rights to Sunosi from Jazz Pharmaceuticals (JAZZ - Free Report) in May 2022. It began selling Sunosi in the U.S. market in May 2022 and in certain international markets in November 2022.
Jazz received approval for Sunosi as a treatment for narcolepsy in 2019.
The acquisition of Sunosi from Jazz diversified Axsome’s portfolio of drugs. In the first nine months of 2024, Sunosi’s net product sales were $65.6 million, reflecting an increase of almost 30% year over year. The drug has become an important revenue driver for Axsome.
In the past 60 days, estimates for Harmony Biosciences’ earnings per share have increased from $2.64 to $3.22 for 2025. In the past year, shares of HRMY have rallied 25.3%.
HRMY’s earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 147.24%.
In the past 60 days, estimates for BioMarin’s earnings per share have moved up from $3.94 to $4.02 for 2025. In the past year, shares of BMRN have plunged 27.6%.
BMRN’s earnings beat estimates in each of the trailing four quarters, the average surprise being 28.70%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Axsome Gets FDA Nod for New Migraine Drug Symbravo, Stock Rises
Axsome Therapeutics, Inc. (AXSM - Free Report) announced that the FDA has approved Symbravo (meloxicam and rizatriptan) for the acute treatment of migraine with or without aura in adults.
Per the company, Symbravo, a novel, oral medicine, offers a multi-mechanistic approach to treating migraine. It targets multiple pathways underlying a migraine attack.
AXSM expects to launch Symbravo in the United States in about four months.
Shares of AXSM were up 3.5% on Jan. 30 following the news announcement.
The stock has rallied 20.8% in the past year against the industry’s decline of 10.2%.
Image Source: Zacks Investment Research
More on AXSM's Newest Migraine Drug
The FDA for Symbravo was based on data from a comprehensive clinical program that consisted of multiple phase III studies, the MOMENTUM study, INTERCEPT and the phase III MOVEMENT long-term open-label safety study.
Data from the phase III MOMENTUM and INTERCEPT studies showed that 77% and 85% of patients who were treated with Symbravo did not require rescue medication within 24 hours after the dose, respectively.
Data from both these studies showed that treatment with Symbravo led to a statistically significantly greater percentage of patients achieving pain freedom and freedom from their most bothersome symptom versus placebo, two hours after dosing.
The MOVEMENT study demonstrated the long-term safety of Symbravo in the given patient population.
Also, treatment with Symbravo demonstrated superior efficacy across a broad range of migraine severity (mild, moderate, and severe).
FDA Nod for Symbravo Diversifies AXSM's Product Portfolio
The latest FDA nod for Symbravo diversifies Axsome’s commercial drug portfolio. The company currently markets Auvelity (AXS-05) for treating major depressive disorder (MDD) and Sunosi (solriamfetol) for treating narcolepsy.
Auvelity was launched in the United States in 2022 for the treatment of MDD, making it the first approved drug in the company’s portfolio. The drug generated sales worth $198.8 in the first nine months of 2024, reflecting an increase of 145.4% year over year in the United States.
Axsome’s second marketed drug, Sunosi, is approved for treating narcolepsy. The company acquired U.S. rights to Sunosi from Jazz Pharmaceuticals (JAZZ - Free Report) in May 2022. It began selling Sunosi in the U.S. market in May 2022 and in certain international markets in November 2022.
Jazz received approval for Sunosi as a treatment for narcolepsy in 2019.
The acquisition of Sunosi from Jazz diversified Axsome’s portfolio of drugs. In the first nine months of 2024, Sunosi’s net product sales were $65.6 million, reflecting an increase of almost 30% year over year. The drug has become an important revenue driver for Axsome.
AXSM's Zacks Rank & Stocks to Consider
Axsome currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Harmony Biosciences Holdings, Inc. (HRMY - Free Report) and BioMarin Pharmaceutical Inc. (BMRN - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for Harmony Biosciences’ earnings per share have increased from $2.64 to $3.22 for 2025. In the past year, shares of HRMY have rallied 25.3%.
HRMY’s earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 147.24%.
In the past 60 days, estimates for BioMarin’s earnings per share have moved up from $3.94 to $4.02 for 2025. In the past year, shares of BMRN have plunged 27.6%.
BMRN’s earnings beat estimates in each of the trailing four quarters, the average surprise being 28.70%.